Hepatology Research最新文献

{"title":"Diagnostic Performance of Serum Autotaxin for Staging Liver Fibrosis: A Comparative Study With Other Noninvasive Liver Fibrosis Tests in Chronic Liver Disease.","authors":"Hideyuki Tamai, Jumpei Okamura","doi":"10.1111/hepr.70113","DOIUrl":"10.1111/hepr.70113","url":null,"abstract":"<p><strong>Aim: </strong>Serum autotaxin (ATX) has emerged as a promising biomarker for liver fibrosis, despite known sex-related variability. In addition to the conventional enzyme immunoassay (EIA-ATX), newer methods have been developed: a chemiluminescent enzyme immunoassay (CL-ATX), which enables rapid measurement with smaller sample volumes, and an enzyme assay (E-ATX), compatible with routine clinical chemistry analyzers, thereby enhancing accessibility. This study aimed to evaluate the diagnostic performance of ATX in comparison with other noninvasive tests for liver fibrosis.</p><p><strong>Methods: </strong>A total of 357 patients with chronic liver disease who underwent liver biopsy and had measurements of serum MAC-2 binding protein glycosylation isomer (M2BPGi) and shear wave measurement (SWM) were analyzed. ATX levels were measured using stored serum samples with both EIA-ATX and CL-ATX. Additionally, in 317 of these patients, ATX was also measured using the E-ATX method.</p><p><strong>Results: </strong>In male patients, the area under the receiver operating characteristic curve (AUROC) values for predicting significant fibrosis (≥ fibrosis Stage 2) were 0.862 for SWM, 0.836 for M2BPGi, 0.814 for the fibrosis-4 index, 0.758 for platelet count, 0.800 for EIA-ATX, 0.790 for CL-ATX, and 0.783 for E-ATX. In female patients, the corresponding AUROC values were 0.834, 0.828, 0.857, 0.786, 0.805, 0.804, and 0.805, respectively. No significant differences were observed in AUROC values between ATX and other noninvasive liver fibrosis tests, nor among the different ATX measurement methods.</p><p><strong>Conclusions: </strong>ATX demonstrated acceptable diagnostic performance for significant fibrosis, comparable to established noninvasive tests. The availability of E-ATX on routine chemistry analyzers highlights its potential as a practical biomarker for primary care and health checkups.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"692-706"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter: Enhancing Robustness in Prognostic Biomarker Research: A Letter on Validating Model Assumptions and Handling Zero Events.","authors":"Yuta Myojin, Hayato Hikita","doi":"10.1111/hepr.70120","DOIUrl":"10.1111/hepr.70120","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"879-880"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-COVID-19 Changes in Body Composition and Adiposity in Patients With Chronic Liver Disease: A Longitudinal Study From Japan.","authors":"Akira Uchiyama, Kazuyoshi Kon, Masahiro Tada, Kei Ishizuka, Maki Morinaga, Hiroo Fukada, Reiko Yaginuma, Kyoko Fukuhara, Shunhei Yamashina, Kenichi Ikejima","doi":"10.1111/hepr.70114","DOIUrl":"10.1111/hepr.70114","url":null,"abstract":"<p><strong>Aim: </strong>The COVID-19 pandemic markedly affected lifestyle behaviors and metabolic health worldwide. Patients with chronic liver disease (CLD) are particularly vulnerable to such disruptions; however, how these effects changed after daily life returned to normal remains unclear. This study examined changes in body composition, hepatic steatosis, and liver fibrosis during the with-COVID-19 and after-COVID-19 periods, with a focus on potential sex-specific differences.</p><p><strong>Methods: </strong>A total of 187 patients with CLD underwent FibroScan and bioelectrical impedance analysis at three time points: before COVID-19 (2019-2020), during the pandemic (2020-2021), and after the disease was reclassified as Category V in Japan (2023-2024). Changes in obesity, hepatic steatosis, and skeletal muscle mass, as well as their associations with liver stiffness, were evaluated using univariate and multivariate analyses.</p><p><strong>Results: </strong>Obesity and hepatic steatosis worsened during the pandemic but improved in the after-COVID-19 period, particularly in men. Overall skeletal muscle mass remained stable, whereas lower-limb muscle mass increased in women. The skeletal muscle index-to-BMI ratio increased in both sexes, showing relative preservation of muscle mass. In univariate analyses, changes in liver stiffness (ΔLSM) were associated with muscle mass parameters only in women; however, these associations did not remain significant as independent predictors after multivariate adjustment.</p><p><strong>Conclusions: </strong>As lifestyles normalized after the pandemic, patients with CLD showed improvements in obesity and hepatic steatosis. Women demonstrated recovery of lower-limb muscle mass, suggesting greater susceptibility to pandemic-related lifestyle changes. Although muscle mass changes were not independently associated with liver stiffness in multivariate analyses, these findings should be interpreted cautiously; nonetheless, they suggest that sex-specific factors may warrant consideration when supporting comprehensive health management in patients with CLD.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"707-715"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145862835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.","authors":"Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Hironori Tanaka, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Yoshihide Ueda, Soo Ki Kim, Fujimasa Tada, Shinichiro Nakamura, Takanori Matsuura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Jumpei Okamura, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada","doi":"10.1111/hepr.70115","DOIUrl":"10.1111/hepr.70115","url":null,"abstract":"<p><strong>Aim: </strong>Evidence regarding the optimal first-line immune checkpoint inhibitor (ICI) regimen for treating unresectable hepatocellular carcinoma (uHCC) with Child-Pugh class B (CP-B) liver function remains limited. This study compared atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre group) in real-world settings.</p><p><strong>Methods: </strong>In this multicenter retrospective study, 211 consecutive patients with uHCC and CP-B liver function who underwent ICI-based therapy as a first-line therapy were analyzed. Treatment responses, survival outcomes, albumin-bilirubin (ALBI) score changes, and adverse events were evaluated. Survival analyses were adjusted using inverse probability weighting (IPW).</p><p><strong>Results: </strong>The median progression-free survival associated with the Atez/Bev and Dur/Tre regimens was 5.0 and 3.5 months, respectively; the median corresponding overall survival was 10.5 and 12.4 months. After IPW adjustment, no significant differences were observed in progression-free or overall survival. The Atez/Bev regimen-associated disease control rate was significantly higher (75.2% vs. 55.0%, p = 0.02). The Dur/Tre regimen, meanwhile, was associated with a significantly higher immune-related adverse event incidence (10.5% vs. 32.7%, p < 0.01) and a greater need for high-dose corticosteroid treatment. In contrast, the Atez/Bev regimen resulted in a progressive decrease in ALBI scores, whereas the Dur/Tre regimen maintained the hepatic functional reserve.</p><p><strong>Conclusions: </strong>The Atez/Bev and Dur/Tre regimens afforded comparable survival outcomes but differed substantially in safety and effects on the hepatic functional reserve. Given the trade-off between immunotoxicity and liver function preservation, treatment selection for CP-B liver function should be individualized, considering baseline hepatic reserve, tolerability, and anticipated treatment trajectory.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"716-724"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelets as Context-Dependent Modulators of Hepatic Microvascular Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Kazuhiro Takahashi, Naoyuki Hasegawa, Tatsuya Oda","doi":"10.1111/hepr.70124","DOIUrl":"10.1111/hepr.70124","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"639-641"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncogenic Signaling Activation and Potential Biomarkers in Congestive Hepatopathy Revealed by Proteomic Analysis.","authors":"Yoshihito Morimoto, Kiyotaka Go, Kentaro Suzuki, Hidenori Yamamoto, Yoshie Fukasawa, Naoki Ohashi, Yoshiyuki Takahashi, Taichi Kato","doi":"10.1111/hepr.70133","DOIUrl":"10.1111/hepr.70133","url":null,"abstract":"<p><strong>Aim: </strong>Fontan surgery improves outcomes in univentricular heart disease; however, some patients develop severe Fontan-associated liver disease (FALD). Even during adolescence, hepatocellular carcinoma occurs in some patients with FALD, although the mechanism remains unclear. In this study, we conducted proteomic analyses of liver tissues obtained using laser capture microdissection (LCM) and serum samples to investigate FALD-related peripheral liver oncogenic factors and explore potential biomarkers.</p><p><strong>Methods: </strong>Ten-week-old mice underwent sham surgery, and age-matched mice underwent partial ligation of the suprahepatic inferior vena cava as a congestive hepatopathy (CH) model. Control liver (CL) and serum were collected from the control models, whereas peripheral congestive liver (PCL) and serum were obtained from the CH models. LCM-isolated liver and serum samples were subjected to qualitative and quantitative proteomic analyses. Differentially expressed proteins (DEPs) were identified by mass spectrometry.</p><p><strong>Results: </strong>We identified 3904 hepatic proteins and 2947 serum proteins. Cancer-related proteins were upregulated in PCL, whereas hepatoprotective proteins were reduced compared with those in CL. Enrichment analysis revealed the upregulation of oncogenic signaling pathways in PCL. Twenty DEPs (e.g., transforming growth factor-beta-induced protein ig-h3, complement C1q subcomponent subunit A, and Dickkopf-related protein 3) were concurrently increased in PCL and serum of the CH models.</p><p><strong>Conclusions: </strong>PCL upregulated oncogenic proteins and activated oncogenic signaling pathways. DEPs detectable in the liver and serum indicate potential FALD biomarkers. These findings offer insights into the pathophysiology of FALD and hepatocarcinogenesis and support the development of novel diagnostic and therapeutic strategies.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"784-794"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146085667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.","authors":"Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C Nelson Hayes, Masataka Tsuge, Shiro Oka","doi":"10.1111/hepr.70131","DOIUrl":"10.1111/hepr.70131","url":null,"abstract":"<p><strong>Background: </strong>There is a paucity of data regarding the efficacy and safety of lenvatinib as a second-line treatment following first-line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre).</p><p><strong>Methods: </strong>This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after progression on Dur + Tre therapy, conducted at five institutions, including Hiroshima University. In cases where the multidisciplinary team determined that concurrent transcatheter arterial chemoembolization (TACE) would be beneficial, on-demand TACE was administered concomitantly with lenvatinib. The therapeutic response and safety profile of lenvatinib were evaluated in all enrolled patients, including those who underwent TACE.</p><p><strong>Results: </strong>The objective response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS) for Dur + Tre and subsequent lenvatinib treatment were 14.3%/30.7%, 57.1%/61.5%, and 2.4/2.3 months, respectively. Five patients (35.7%) received combined lenvatinib and TACE therapy. Among these, one patient each with stable disease (SD) and progressive disease (PD) on Dur + Tre improved to partial response (PR) during lenvatinib therapy. Two patients (14.3%) remained on lenvatinib at the time of analysis. Six patients (42.9%) transitioned to subsequent lines of systemic therapy, all receiving atezolizumab combined with bevacizumab. Overall, five patients (35.7%) had died at the data cutoff, with a median overall survival (OS) of 18.4 months. Grade 3 or higher adverse events (AEs) were observed in 7 patients (50%) across both Dur + Tre and lenvatinib treatment phases.</p><p><strong>Conclusions: </strong>Lenvatinib administered after progression on Dur + Tre demonstrates promising efficacy and an acceptable safety profile in patients who tolerate the therapy. The integration of TACE in suitable candidates warrants further exploration, and timely transition to subsequent systemic therapies should be considered when adverse events or intolerance are encountered.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"861-866"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Variceal Therapy and Transitional Care in Pediatric Portal Hypertension: A Review With a Focus on Long-Term Outcomes and Adherence.","authors":"Hisashi Hidaka","doi":"10.1111/hepr.70180","DOIUrl":"10.1111/hepr.70180","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"645-647"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Escape From Disulfidptosis and Ferroptosis Drives Highly Aggressive, Hypermetabolic Hepatocellular Carcinoma.","authors":"Junya Mita, Shinji Itoh, Takeo Toshima, Yoshiyuki Kitamura, Norifumi Iseda, Takuro Isoda, Kousei Ishigami, Shinichi Aishima, Yoshinao Oda, Tomoharu Yoshizumi","doi":"10.1111/hepr.70116","DOIUrl":"10.1111/hepr.70116","url":null,"abstract":"<p><strong>Aim: </strong>The cystine/glutamate antiporter xCT facilitates cystine uptake and glutathione synthesis and suppresses ferroptosis. However, its role in hepatocellular carcinoma (HCC), particularly in glucose metabolism and disulfidptosis, remains unclear. We examined the prognostic value of xCT expression and tumor 18F-fluorodeoxyglucose (FDG) uptake as well as their association with tumor biology.</p><p><strong>Methods: </strong>We retrospectively analyzed 345 patients with HCC who underwent hepatic resection. Immunohistochemical staining for xCT was performed in all 345 cases, and its associations with clinicopathological characteristics and survival were evaluated. Among these, 108 patients also underwent preoperative 18F-FDG positron emission tomography/computed tomography (PET/CT). In this subset, tumor FDG uptake was quantified and its relationship with xCT expression and patient prognosis was assessed.</p><p><strong>Results: </strong>Patients with xCT-positive tumors had significantly worse overall survival compared with those with xCT-negative tumors (10-year, 42.6% vs. 75.2%; log-rank test, p < 0.0001). Among 108 patients with HCC who underwent PET/CT, xCT positivity was an independent predictor of poor prognosis in multivariate analysis (hazard ratio, 3.17; 95% confidence interval, 1.47-6.87; p = 0.0034). In addition, xCT expression correlated with FDG uptake (p = 0.0335). Importantly, tumors that were both xCT-positive and had high FDG uptake exhibited the poorest prognosis (log-rank test, p = 0.0405).</p><p><strong>Conclusions: </strong>High xCT expression combined with elevated FDG uptake may identify a subset of patients with HCC who have poor prognoses and dual resistance to ferroptosis and disulfidptosis. These findings highlight the potential of xCT as both a prognostic biomarker and therapeutic target for aggressive HCC.</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"725-734"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-to Pretreatment Ratio of Serum CXCL10 Level Predicts Short-Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct-Acting Antiviral Therapy.","authors":"Takanori Suzuki, Kentaro Matsuura, Yuki Tahata, Hayato Hikita, Masaru Enomoto, Atsunori Tsuchiya, Daiki Miki, Hiroshi Yatsuhashi, Hidekatsu Kuroda, Taro Yamashita, Hitoshi Yoshiji, Nobuharu Tamaki, Seiichi Mawatari, Hisamitsu Miyaaki, Yasuhiro Asahina, Yoichi Hiasa, Yoshihito Uchida, Yasunari Nakamoto, Taro Takami, Takahiro Kodama, Tetsuo Takehara","doi":"10.1111/hepr.70139","DOIUrl":"10.1111/hepr.70139","url":null,"abstract":"<p><strong>Aim: </strong>The prognostic value of serum C-X-C motif chemokine ligand 10 (CXCL10) levels for liver function was investigated in hepatitis C virus (HCV)-infected patients with compensated or decompensated cirrhosis (cLC and dLC, respectively) following treatment with direct-acting antivirals (DAAs).</p><p><strong>Methods: </strong>In this nationwide study involving multiple centers, 164 HCV-related liver cirrhosis patients (95 with cLC and 69 with dLC), who underwent treatment with DAAs, were analyzed. Serum levels of CXCL10 were assessed at the baseline (pre-CXCL10) and at 12 or 24 weeks after the end of therapy (post-CXCL10). Associations between CXCL10 levels and liver function after DAA therapy were evaluated.</p><p><strong>Results: </strong>Of the 164 study patients, the albumin-bilirubin (ALBI) grade was reduced to Grade 1 in 85 patients at one year after end of therapy (EOT1Y). Serum CXCL10 ratios (post-CXCL10/pre-CXCL10 levels) were significantly lower in ALBI Grade 1 patients than the others (p = 0.014) at EOT1Y. Receiver operating curve analysis for distinguishing ALBI Grade 1 at EOT1Y demonstrated that the area under the curve was 0.611, with an optimal cutoff value of 0.504. Multivariate analysis revealed that body mass index (BMI; odds ratio [OR] 0.816; p < 0.001), absence of ascites (OR 3.340; p = 0.003), FIB-4 index (OR 0.872; p = 0.026), and serum CXCL10 ratios < 0.504 (OR 2.630; p = 0.010) were independently correlated to ALBI Grade 1 at EOT1Y.</p><p><strong>Conclusions: </strong>The post-to pretreatment serum CXCL10 ratio was independently associated with short-term liver function outcome following HCV eradication in cirrhotic patients.</p><p><strong>Registry and registration nos: </strong>This study was registered to the University Hospital Medical Information Network (36,150).</p>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"840-852"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}